{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T19:07:43Z","timestamp":1759777663682},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2014,7,24]],"date-time":"2014-07-24T00:00:00Z","timestamp":1406160000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1007\/s00280-014-2538-1","type":"journal-article","created":{"date-parts":[[2014,7,23]],"date-time":"2014-07-23T07:54:54Z","timestamp":1406102094000},"page":"611-615","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Liposomal anthracycline chemotherapy and the risk of second malignancies in patients with Kaposi\u2019s sarcoma (KS)"],"prefix":"10.1007","volume":"74","author":[{"given":"M.","family":"Bendle","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Pealing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Papanastasopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Bower","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,7,24]]},"reference":[{"key":"2538_CR1","unstructured":"National Cancer Institute. Provocative questions: identifying perplexing problems to drive progress against cancer. http:\/\/provocativequestions.nci.nih.gov\/rfa\/mainquestions_listview?mqCategory=Group+B"},{"issue":"4","key":"2538_CR2","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.currproblcancer.2012.03.008","volume":"36","author":"S Lloyd","year":"2012","unstructured":"Lloyd S, Park HS, Decker RH, Wilson LD, Yu JB (2012) Using the surveillance, epidemiology, and end results database to investigate rare cancers, second malignancies, and trends in epidemiology, treatment, and outcomes. Curr Probl Cancer 36(4):191\u2013199","journal-title":"Curr Probl Cancer"},{"issue":"4","key":"2538_CR3","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1080\/028418602760169361","volume":"41","author":"LB Travis","year":"2002","unstructured":"Travis LB (2002) Therapy-associated solid tumors. Acta Oncol 41(4):323\u2013333","journal-title":"Acta Oncol"},{"issue":"30","key":"2538_CR4","doi-asserted-by":"crossref","first-page":"3734","DOI":"10.1200\/JCO.2012.41.8681","volume":"30","author":"ME Wood","year":"2012","unstructured":"Wood ME, Vogel V, Ng A, Foxhall L, Goodwin P, Travis LB (2012) Second malignant neoplasms: assessment and strategies for risk reduction. J Clin Oncol 30(30):3734\u20133745","journal-title":"J Clin Oncol"},{"issue":"7","key":"2538_CR5","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1093\/jnci\/87.7.524","volume":"87","author":"LB Travis","year":"1995","unstructured":"Travis LB, Curtis RE, Glimelius B, Holowaty EJ, Van Leeuwen FE, Lynch CF et al (1995) Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin\u2019s lymphoma. J Natl Cancer Inst 87(7):524\u2013530","journal-title":"J Natl Cancer Inst"},{"issue":"14","key":"2538_CR6","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1093\/jnci\/92.14.1165","volume":"92","author":"LB Travis","year":"2000","unstructured":"Travis LB, Andersson M, Gospodarowicz M, van Leeuwen FE, Bergfeldt K, Lynch CF et al (2000) Treatment-associated leukemia following testicular cancer. J Natl Cancer Inst 92(14):1165\u20131171","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"2538_CR7","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1182\/blood-2003-04-1124","volume":"103","author":"M Andre","year":"2004","unstructured":"Andre M, Mounier N, Leleu X, Sonet A, Brice P, Henry-Amar M et al (2004) Second cancers and late toxicities after treatment of aggressive non-Hodgkin lymphoma with the ACVBP regimen: a GELA cohort study on 2,837 patients. Blood 103(4):1222\u20131228","journal-title":"Blood"},{"issue":"10","key":"2538_CR8","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1200\/JCO.2005.04.2200","volume":"24","author":"NY Mudie","year":"2006","unstructured":"Mudie NY, Swerdlow AJ, Higgins CD, Smith P, Qiao Z, Hancock BW et al (2006) Risk of second malignancy after non-Hodgkin\u2019s lymphoma: a British cohort study. J Clin Oncol 24(10):1568\u20131574","journal-title":"J Clin Oncol"},{"issue":"10","key":"2538_CR9","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.3324\/haematol.11034","volume":"92","author":"G Leone","year":"2007","unstructured":"Leone G, Pagano L, Ben-Yehuda D, Voso MT (2007) Therapy-related leukemia and myelodysplasia: susceptibility and incidence. Haematologica 92(10):1389\u20131398","journal-title":"Haematologica"},{"issue":"26","key":"2538_CR10","doi-asserted-by":"crossref","first-page":"11014","DOI":"10.1073\/pnas.0704002104","volume":"104","author":"AM Azarova","year":"2007","unstructured":"Azarova AM, Lyu YL, Lin CP, Tsai YC, Lau JY, Wang JC et al (2007) Roles of DNA topoisomerase II isozymes in chemotherapy and secondary malignancies. Proc Natl Acad Sci USA 104(26):11014\u201311019","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"2538_CR11","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1093\/jnci\/djk052","volume":"99","author":"TO Henderson","year":"2007","unstructured":"Henderson TO, Whitton J, Stovall M, Mertens AC, Mitby P, Friedman D et al (2007) Secondary sarcomas in childhood cancer survivors: a report from the childhood cancer survivor study. J Natl Cancer Inst 99(4):300\u2013308","journal-title":"J Natl Cancer Inst"},{"issue":"7","key":"2538_CR12","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1038\/sj.bjc.6605325","volume":"101","author":"JL Bermejo","year":"2009","unstructured":"Bermejo JL, Sundquist J, Hemminki K (2009) Bladder cancer in cancer patients: population-based estimates from a large Swedish study. Br J Cancer 101(7):1091\u20131099","journal-title":"Br J Cancer"},{"issue":"7","key":"2538_CR13","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1200\/JCO.2010.28.9777","volume":"29","author":"C Tarella","year":"2011","unstructured":"Tarella C, Passera R, Magni M, Benedetti F, Rossi A, Gueli A et al (2011) Risk factors for the development of secondary malignancy after high-dose chemotherapy and autograft, with or without rituximab: a 20-year retrospective follow-up study in patients with lymphoma. J Clin Oncol 29(7):814\u2013824","journal-title":"J Clin Oncol"},{"issue":"31","key":"2538_CR14","doi-asserted-by":"crossref","first-page":"4096","DOI":"10.1200\/JCO.2011.34.8268","volume":"29","author":"AJ Swerdlow","year":"2011","unstructured":"Swerdlow AJ, Higgins CD, Smith P, Cunningham D, Hancock BW, Horwich A et al (2011) Second cancer risk after chemotherapy for Hodgkin\u2019s lymphoma: a collaborative British cohort study. J Clin Oncol 29(31):4096\u20134104","journal-title":"J Clin Oncol"},{"issue":"8","key":"2538_CR15","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1200\/JCO.2002.08.021","volume":"20","author":"AK Ng","year":"2002","unstructured":"Ng AK, Bernardo MP, Weller E, Backstrand KH, Silver B, Marcus KC et al (2002) Long-term survival and competing causes of death in patients with early-stage Hodgkin\u2019s disease treated at age 50 or younger. J Clin Oncol 20(8):2101\u20132108","journal-title":"J Clin Oncol"},{"issue":"9581","key":"2538_CR16","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0140-6736(07)61050-2","volume":"370","author":"AE Grulich","year":"2007","unstructured":"Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM (2007) Incidence of cancers in people with HIV\/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 370(9581):59\u201367","journal-title":"Lancet"},{"issue":"18","key":"2538_CR17","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1056\/NEJM199505043321802","volume":"332","author":"E Cesarman","year":"1995","unstructured":"Cesarman E, Chang Y, Moore PS, Said JW, Knowles DM (1995) Kaposi\u2019s sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N Engl J Med 332(18):1186\u20131191","journal-title":"N Engl J Med"},{"issue":"4","key":"2538_CR18","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1182\/blood.V95.4.1406.004k26_1406_1412","volume":"95","author":"N Dupin","year":"2000","unstructured":"Dupin N, Diss TL, Kellam P, Tulliez M, Du MQ, Sicard D et al (2000) HHV-8 is associated with a plasmablastic variant of Castleman disease that is linked to HHV-8-positive plasmablastic lymphoma. Blood 95(4):1406\u20131412","journal-title":"Blood"},{"issue":"4","key":"2538_CR19","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1182\/blood.V86.4.1276.bloodjournal8641276","volume":"86","author":"J Soulier","year":"1995","unstructured":"Soulier J, Grollet L, Oksenhendler E, Cacoub P, Cazals-Hatem D, Babinet P et al (1995) Kaposi\u2019s sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman\u2019s disease. Blood 86(4):1276\u20131280","journal-title":"Blood"},{"issue":"5","key":"2538_CR20","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1200\/JCO.2013.51.6757","volume":"32","author":"M, Bower","year":"2014","unstructured":"Bower M, Dalla Pria A, Coyle C, Andrews E, Tittle V, Dhoot S et al (2014) Prospective stage-stratified approach to AIDS-related Kaposi\u2019s sarcoma. J Clin Oncol 32(5):409\u2013414","journal-title":"J Clin Oncol"},{"issue":"Suppl 2","key":"2538_CR21","first-page":"1","volume":"15","author":"M Bower","year":"2014","unstructured":"Bower M, Palfreeman A, Alfa-Wali M, Bunker C, Burns F, Churchill D et al (2014) British HIV Association guidelines for HIV-associated malignancies 2014. HIV Med 15(Suppl 2):1\u201392","journal-title":"HIV Med"},{"key":"2538_CR22","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1200\/JCO.1989.7.9.1201","volume":"7","author":"S Krown","year":"1989","unstructured":"Krown S, Metroka C, Wernz JC (1989) Kaposi\u2019s sarcoma in the acquired immune deficiency syndrome: a proposal for uniform evaluation, response, and staging criteria. AIDS Clinical Trials Group Oncology Committee. J Clin Oncol 7:1201\u20131207","journal-title":"J Clin Oncol"},{"key":"2538_CR23","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","volume":"53","author":"E Kaplan","year":"1958","unstructured":"Kaplan E, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457\u2013481","journal-title":"J Am Stat Assoc"},{"key":"2538_CR24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/bjc.1977.1","volume":"35","author":"R Peto","year":"1977","unstructured":"Peto R, Pike M, Armitage P, Breslow N, Cox D, Howard S et al (1977) Design and analysis of randomised clinical trials requiring prolonged observation of each patient II: analysis and examples. Br J Cancer 35:1\u201339","journal-title":"Br J Cancer"},{"issue":"8","key":"2538_CR25","first-page":"1305","volume":"9","author":"PH Domer","year":"1995","unstructured":"Domer PH, Head DR, Renganathan N, Raimondi SC, Yang E, Atlas M (1995) Molecular analysis of 13 cases of MLL\/11q23 secondary acute leukemia and identification of topoisomerase II consensus-binding sequences near the chromosomal breakpoint of a secondary leukemia with the t(4;11). Leukemia 9(8):1305\u20131312","journal-title":"Leukemia"},{"issue":"9","key":"2538_CR26","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1200\/JCO.1992.10.9.1444","volume":"10","author":"J Pedersen-Bjergaard","year":"1992","unstructured":"Pedersen-Bjergaard J, Sigsgaard TC, Nielsen D, Gjedde SB, Philip P, Hansen M et al (1992) Acute monocytic or myelomonocytic leukemia with balanced chromosome translocations to band 11q23 after therapy with 4-epi-doxorubicin and cisplatin or cyclophosphamide for breast cancer. J Clin Oncol 10(9):1444\u20131451","journal-title":"J Clin Oncol"},{"issue":"3","key":"2538_CR27","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1046\/j.1365-2141.2000.02240.x","volume":"110","author":"S Zompi","year":"2000","unstructured":"Zompi S, Legrand O, Bouscary D, Blanc CM, Picard F, Casadevall N et al (2000) Therapy-related acute myeloid leukaemia after successful therapy for acute promyelocytic leukaemia with t(15;17): a report of two cases and a review of the literature. Br J Haematol 110(3):610\u2013613","journal-title":"Br J Haematol"},{"issue":"1","key":"2538_CR28","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/2162-3619-1-10","volume":"1","author":"SM Rafiyath","year":"2012","unstructured":"Rafiyath SM, Rasul M, Lee B, Wei G, Lamba G, Liu D (2012) Comparison of safety and toxicity of liposomal doxorubicin vs. conventional anthracyclines: a meta-analysis. Exp. Hematol Oncol 1(1):10","journal-title":"Hematol Oncol"},{"issue":"1","key":"2538_CR29","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1097\/QAI.0b013e3181b563e7","volume":"53","author":"KM Harrison","year":"2010","unstructured":"Harrison KM, Song R, Zhang X (2010) Life expectancy after HIV diagnosis based on national HIV surveillance data from 25 states, United States. J Acquir Immune Defic Syndr 53(1):124\u2013130","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"18","key":"2538_CR30","doi-asserted-by":"crossref","first-page":"3447","DOI":"10.1200\/JCO.2003.01.096","volume":"21","author":"M Herida","year":"2003","unstructured":"Herida M, Mary-Krause M, Kaphan R, Cadranel J, Poizot-Martin I, Rabaud C et al (2003) Incidence of non-AIDS-defining cancers before and during the highly active antiretroviral therapy era in a cohort of human immunodeficiency virus-infected patients. J Clin Oncol 21(18):3447\u20133453","journal-title":"J Clin Oncol"},{"issue":"6","key":"2538_CR31","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1200\/JCO.2008.19.6626","volume":"27","author":"T Powles","year":"2009","unstructured":"Powles T, Robinson D, Stebbing J, Shamash J, Nelson M, Gazzard B et al (2009) Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancers in people with HIV infection. J Clin Oncol 27(6):884\u2013890","journal-title":"J Clin Oncol"},{"issue":"9","key":"2538_CR32","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1093\/jnci\/djr076","volume":"103","author":"MS Shiels","year":"2011","unstructured":"Shiels MS, Pfeiffer RM, Gail MH, Hall HI, Li J, Chaturvedi AK et al (2011) Cancer burden in the HIV-infected population in the United States. J Natl Cancer Inst 103(9):753\u2013762","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"2538_CR33","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1002\/cncr.25547","volume":"117","author":"EP Simard","year":"2011","unstructured":"Simard EP, Pfeiffer RM, Engels EA (2011) Cumulative incidence of cancer among individuals with acquired immunodeficiency syndrome in the United States. Cancer 117(5):1089\u20131096","journal-title":"Cancer"},{"issue":"1","key":"2538_CR34","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/ijc.23487","volume":"123","author":"EA Engels","year":"2008","unstructured":"Engels EA, Biggar RJ, Hall HI, Cross H, Crutchfield A, Finch JL et al (2008) Cancer risk in people infected with human immunodeficiency virus in the United States. Int J Cancer 123(1):187\u2013194","journal-title":"Int J Cancer"},{"issue":"3","key":"2538_CR35","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/2047-783X-16-3-101","volume":"16","author":"M Vogel","year":"2011","unstructured":"Vogel M, Friedrich O, Luchters G, Holleczek B, Wasmuth JC, Anadol E et al (2011) Cancer risk in HIV-infected individuals on HAART is largely attributed to oncogenic infections and state of immunocompetence. Eur J Med Res 16(3):101\u2013107","journal-title":"Eur J Med Res"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-014-2538-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-014-2538-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-014-2538-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,22]],"date-time":"2020-08-22T13:59:20Z","timestamp":1598104760000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-014-2538-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7,24]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["2538"],"URL":"https:\/\/doi.org\/10.1007\/s00280-014-2538-1","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,7,24]]}}}